Groprinosin
From PeptideSciences101, the open peptide reference. · Last updated: October 7, 2025
This article is a stub. A peer-reviewed deep-dive is in preparation. Help contribute to expand it.
…
Overview
Inosine complex that enhances immune response to viral infections.
Reported benefits
Antiviral activity, immune enhancement, lymphocyte stimulation
Protocols & dosing
Typical dosage: 500-1000 mg (three times daily).
Detailed dosing protocols have not yet been catalogued.
FDA & legal status
Groprinosin is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.
| Country | Status |
|---|---|
| United States | Research use only |
| United Kingdom | Prescription-only / not licensed |
| Canada | Prescription-only / Schedule F if licensed |
| Australia | TGA-scheduled |
Vendor information
PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.
Side effects & safety
Reported side effects: Possible GI upset, elevated uric acid
References
No external sources have been catalogued for this article yet.
Related peptides
- AMP-K — Metabolic immune support
- Beta-Glucan Peptide — Immune activating complex
- Icotrokinra — Oral macrocyclic peptide. First-in-class IL-23 receptor antagonist. FDA approved March 17, 2026 for plaque psoriasis.
- Imunofan — Russian immune peptide
- KPV — Anti-inflammatory immune peptide
- LL-37 — Antimicrobial defense peptide
Categories: Immune Support